COMMUNIQUÉS West-GlobeNewswire

Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026
26/10/2026
50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 Unprecedented Efficacy in Both Refractory Undifferentiated [...]
TILT Biotherapeutics Presents Encouraging Phase 1b Results in Ovarian Cancer at ESMO 2026
26/10/2026
Four of nine evaluable patients responded to TILT-123 combined with pembrolizumab and pegylated liposomal doxorubicin, including two complete responses HELSINKI, Finland, Oct. 26, 2026 (GLOBE NEWSWIRE) -- TILT [...]
Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026
26/10/2026
BERKELEY HEIGHTS, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial-stage biotechnology company, today announced that [...]
Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
26/10/2026
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third [...]
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness
26/10/2026
Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense , adding value of approximately $270 million TARRYTOWN, N.Y., Oct. 26, 2026 [...]
Changes in Orion Group’s Executive Team as of 1 January 2027
26/10/2026
ORION CORPORATION STOCK EXCHANGE RELEASE - CHANGES BOARD/MANAGEMENT/AUDITORS 26 October 2026 at 13.00 EET Changes in Orion Group’s Executive Team as of 1 January 2027 To accelerate the implementation of its strategy and [...]
Serapha Bio Announces Positive Interim Safety and Efficacy Data from the SERP-01 Investigator-Initiated Trial Presented at the ERS Alpha-1 Antitrypsin Conference 2026
26/10/2026
Single administration of SERP-01 was associated with increases in total serum AAT above the protective threshold with durable correction out to 10 months Elastase inhibition assay results showed serum approached [...]
Kraig Biocraft Laboratories Launches Performance Yarn Development Program and Ships Spider Silk to Yarn and Aerospace Innovator
26/10/2026
Initiative Builds on First Commercial Yarn Shipment to Create New Constructions and Blends for the Next Generation of Fabrics and Apparel ANN ARBOR, Mich., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, [...]
MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer
26/10/2026
Single agent lorigerlimab demonstrated encouraging preliminary clinical activity in clear cell gynecologic cancer (CCGC) with a confirmed ORR of 25% and a DCR of 44% Safety profile was manageable; further dose [...]
Davion Healthcare Announces US$25 Million Acquisition of Humaskan Medical Technology IP
26/10/2026
Acquisition adds battery-free smart wound dressing and two-minute multi-marker screening test to Davion’s growing healthcare portfolio DUBLIN, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Davion Healthcare Plc (Nasdaq: DAVI) (" [...]
BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives
26/10/2026
BURLINGTON, Mass. and JERUSALEM, Oct. 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today [...]
Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
26/10/2026
Nasdaq closes the minimum bid price matter confirming that the Company has regained compliance PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision [...]
Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC
26/10/2026
XTX501 is a novel PD-1/masked IL-2 bispecific that has the potential to become a foundational backbone regimen for solid tumors Anticipate reporting initial Phase 1 data in the fourth quarter of 2027 Plan to present a [...]
Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
26/10/2026
- Ongoing Pivotal Phase 3 trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel versus standard-of-care chemotherapy in first-line metastatic pancreatic cancer - -MAPKeeper 301 builds on [...]
Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
26/10/2026
Presentation will introduce ART26.12, the first selective FABP5 inhibitor to enter human clinical studies, to the world’s largest gathering of pain professionals Growing body of data supports ART26.12’s potential as a [...]
GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting
26/10/2026
SAN FRANCISCO, CALIFORNIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company [...]
A new scientific avenue for daridorexant: Idorsia to advance development in autism spectrum disorder
26/10/2026
Ad hoc announcement pursuant to Art. 53 LR In a Phase 2 study in pediatric insomnia disorder, in addition to marked improvements in sleep measures, daridorexant 50 mg showed an unexpected pattern of improvement in [...]
DXS International Plc (AQSE: DXSP): Notice of AGM
26/10/2026
26 October 2026 DXS INTERNATIONAL PLC (AQSE: DXSP) Notice of AGM DXS International plc ( AQSE: DXSP ), the UK healthcare technology provider, announces that it has published its Notice of its Annual General Meeting (“ [...]
TME Pharma améliore sa visibilité financière en prolongeant l'échéance de sa dette jusqu'en juin 2028
26/10/2026
TME Pharma améliore sa visibilité financière en prolongeant l'échéance de sa dette jusqu'en juin 2028 Visibilité financière prolongée jusqu'au deuxième trimestre 2028 Tous les détenteurs de dette existants, y compris le [...]

Pages